19 September 2017Americas

Video interview: Allen & Overy on the UPC and CRISPR

The Unified Patent Court (UPC) is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.

This is according to Frits Gerritzen, partner at Allen & Overy, who spoke at the Life Sciences Patent Network North America, hosted by LSIPR in Boston.

“In the short term, the UPC will probably not be as it was originally designed,” said Gerritzen.

He also noted the media attention surrounding CRISPR, adding that this demonstrates that the technology is promising.

Gerritzen went on to discuss an article he presented to a panel at the event on the potential devastating effects of off-target gene mutations that researchers had come across.

To find out more, you can watch the video below.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 September 2017   To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.

More on this story

Americas
22 September 2017   To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.

More on this story

Americas
22 September 2017   To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.